Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
to evaluate the safety and efficacy of Low-dose sirolimus in Kaposiform Hemangioendothelioma
in Chinese children by a prospective, randomized open trial.